Effects of Camelina Oil Supplementation on Lipid Profile and Glycemic Control: A Systematic Review and Dose‒Response Meta-Analysis of Randomized Clinical Trials Publisher Pubmed



Jalili C¹ ; Talebi S² ; Mehrabani S³ ; Bagheri R⁴ ; Wong A⁵ ; Amirian P⁶ ; Zarpoosh M⁶ ; Ghoreishy SM² ; Kermani MAH⁷ ; Moradi S⁸ Show Affiliations
Source: Lipids in Health and Disease Published:2022

Abstract

Background: This systematic review and dose–response meta-analysis of published randomized controlled trials (RCTs) was conducted to determine the effectiveness of camelina oil supplementation (COS) on lipid profiles and glycemic indices. Methods: Relevant RCTs were selected by searching the ISI Web of Science, PubMed, and Scopus databases up to July 1, 2022. RTCs with an intervention duration of less than 2 weeks, without a placebo group, and those that used COS in combination with another supplement were excluded. Weighted mean differences and 95% confidence intervals were pooled by applying a random-effects model, while validated methods examined sensitivity analyses, heterogeneity, and publication bias. Results: Seven eligible RCTs, including 428 individuals, were selected. The pooled analysis revealed that COS significantly improved total cholesterol in studies lasting more than 8 weeks and utilizing dosages lower than 30 g/d compared to the placebo group. The results of fractional polynomial modeling indicated that there were nonlinear dose–response relations between the dose of COS and absolute mean differences in low-density cholesterol, high-density cholesterol, and total cholesterol, but not triglycerides. It appears that the greatest effect of COS oil occurs at the dosage of 20 g/day. Conclusion: The present meta-analysis indicates that COS may reduce cardiovascular disease risk by improving lipid profile markers. Based on the results of this study, COS at dosages lower than 30 g/d may be a beneficial nonpharmacological strategy for lipid control. Further RCTs with longer COS durations are warranted to expand on these results. © 2022, The Author(s).